Benign prostatic hyperplasia: Now we can begin to tailor treatment

Cleveland Clinic Journal of Medicine

Volumn 71, Issue 11, 2004, Pages 857-880

  Gjertson, Carl K ^a   Walmsley, Konstantin ^a   Kaplan, Steven A ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROGEN; ANDROSTANOLONE; BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; CREATININE; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SABAL EXTRACT; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; TESTOSTERONE;

ADULT; AGE; ALTERNATIVE MEDICINE; ANAMNESIS; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; DETRUSOR MUSCLE; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG MECHANISM; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FAMILY HISTORY; HUMAN; INDIVIDUALIZATION; LASER COAGULATION; LIBIDO DISORDER; MALE; MALE TYPE ALOPECIA; MEDICAL DECISION MAKING; META ANALYSIS; MICTURITION DISORDER; MINIMALLY INVASIVE SURGERY; MUSCLE WEAKNESS; NOSE CONGESTION; ORGAN SIZE; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE SURGERY; PROSTATECTOMY; RACE; RESIDUAL VOLUME; RETROGRADE EJACULATION; REVIEW; RISK FACTOR; SYMPTOM; SYSTEMATIC REVIEW; TRANSRECTAL ULTRASONOGRAPHY; TRANSURETHRAL ELECTROVAPORIZATION; TRANSURETHRAL MICROWAVE THERMOTHERAPY; TRANSURETHRAL NEEDLE ABLATION; TRANSURETHRAL RESECTION; URETHROSCOPY; URINALYSIS; URODYNAMICS; UROFLOWMETRY;

EID: 8844219696     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.71.11.857     Document Type: Review

References (48)

1. Albertsen PC, Pellissier JM, Lowe FC, Girman CJ, Roehrborn CG. Economic analysis of finasteride: a model-based approach using data from the Proscar long-term efficacy and safety study. Clin Ther 1999; 21:1006-1024.
2. Littlejohn JO Jr, Ghafar MA, Kang YM, Kaplan SA. Transurethral resection of the prostate: the new old standard. Curr Opin Urol 2002; 12:19-23.
3. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993; 150:85-89.
4. Cabelin MA, Te AE, Kaplan SA. Benign prostatic hyperplasia: challenges for the new millennium. Curr Opin Urol 2000; 10:301-306.
5. Ziada A, Rosenblum M, Crawford ED. Benign prostatic hyperplasia: an overview. Urology 1999; 53(suppl 3a):1-6.
6. Blute ML, Jacobsen SJ, Kaplan SA, et al. Introduction. Evaluation and management of benign prostatic hyperplasia: proceedings of a thought leader conference held March 31, 2001. Urology 2001; 58(suppl 6a):1-4.
7. Jacobsen SJ, Jacobsen DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997; 158:481-487.
8. Roehrborn CG, McConnell JD. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh PC, Retik AB, Vaughn ED, Wein AJ, editors. Campbell's Urology. 8th ed. Philadelphia: WB Saunders Co; 2002:1297-1330.
9. Gerber GS, Kim JH, Contreras BA, Steinberg GD, Rukstalis DB. An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin. Urology 1996; 47:840-844.
10. Narayan P, Tewari A. Overview of alpha-blocker therapy for benign prostatic hyperplasia. Urology 1998; 51(suppl 4A):38-45.
11. Lepor H, Gup DI, Baumann M, Shapiro E. Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia. Urology 1988; 32(suppl):21-26.
12. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003; 170:530-547.
13. Barry MJ, Williford WO, Chang Y, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995; 154:1770-1774.
14. Roehrborn CG, McConnell J, Bonilla J, et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol 2000; 163:13-20.
15. Roehrborn CG, McConnell J, Lieber M, et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 1999; 53:473-480.
16. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med 1995; 332:75-79.
17. Payne CK. Pressure flow studies for prostatism. Urology 1995; 45:552-553.
18. Kaplan SA, Goluboff ET, Olsson CA, Deverka PA, Chmiel JJ. Effect of demographic factors, urinary peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia. Urology 1995; 45:398-405.
19. Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003; 92:257-261.
20. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48:398-405.
21. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338:557-563.
22. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349:215-224.
23. Roehrborn CG, Boyle P, Nickel JC, et al for the ARIA3001 ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60:434-441.
24. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996; 335:533-539.
25. McConnell JD, Roehrborn CG, Bautista AM, et al for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349:2387-2398.
26. Willets KE, Clements MS, Champion S, Ehsman S, Eden JA. Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. BJU Int 2003; 92:267-270.
27. Gordon AE, Shaughnessy AF. Saw palmetto for prostate disorders. Am Fam Physician 2003; 67:1281-1283.
28. Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003; 62:259-264.
29. Kaplan SA. Minimally invasive alternative therapeutic options for lower urinary tract symptoms. Urology 1998; 51(suppl):32-37.
30. Kaplan SA, Laor E, Fatal M, Te AE. Transurethral resection of the prostate versus transurethral electrovaporization of the prostate. J Urol 1998; 159:454-458.
31. Schulman CC, Zlotta AR. Transurethral needle ablation of the prostate (TUNA). A new treatment of benign prostatic hyperplasia using interstitial radiofrequency energy. J Urol (Paris) 1995; 101:33-36.
32. Zlotta AR, Raviv G, Peny MO, Noel JC, Haot J, Schulman CC. Possible mechanisms of action of transurethral needle ablation of the prostate on benign prostatic hyperplasia symptoms: a neurohistochemical study. J Urol 1997; 157:894-899.
33. Campo B, Bergamaschi F, Corrada P, Ordesi G. Transurethral needle ablation (TUNA) of the prostate: a clinical and urodynamic evaluation. Urology 1997; 49:847-850.
34. Zlotta AR, Giannakopoulos X, Maehlum O, Ostrem T, Schulman CC. Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol 2003; 44:89-93.
35. De la Rosette JJ, D'Ancona FC, Debruyne F. Current status of thermotherapy of the prostate. J Urol 1997; 157:430-438.
36. Walmsley K, Kaplan SA. Transurethral microwave thermotherapy for benign prostate hyperplasia - separating truth from marketing hype. In press.
37. Ogden CW, Reddy P, Johnson H, Ramsay JWA, Carter SS. Sham versus transurethral microwave thermotherapy in patients with symptoms of benign prostatic bladder outflow obstruction. Lancet 1993; 341:14-17.
38. Nawrocki JD, Bell TJ, Lawrence WT, Ward JP. A randomized controlled trial of transurethral microwave thermotherapy. Br J Urol 1997; 79:389-393.
39. D'Ancona FC, Francisca EA, Witjes WP, Welling L, Debruyne FM, de la Rosette JJ. High energy thermotherapy versus transurethral resection in the treatment of benign prostatic hyperplasia: results of a prospective randomized study with 1 year of follow-up. J Urol 1997; 158:120-125.
40. Costello AJ, Johnson DE, Bolton DM. Nd:YAG laser ablation of the prostate as a treatment for benign prostatic hypertrophy. Lasers Surg Med 1992; 12:121-124.
41. Cowles RS 3rd, Kabalin JN, Childs S, et al. A prospective randomized comparison of transurethral resection to visual laser ablation of the prostate for treatment of benign prostatic hyperplasia. Urology 1995; 46:155-160.
42. Kursh ED, Concepcion R, Chan S, Hudson P, Ratner M, Eyre R. Interstitial laser coagulation versus transurethral prostate resection for treating benign prostatic obstruction: a randomized trial with 2-year follow-up. Urology 2003; 61:573-578.
43. Aho TF, Gilling PJ. Laser therapy for benign prostatic hyperplasia: a review of recent developments. Curr Opin Urol 2003; 13:39-44.
44. Norby B, Nielsen HV, Frimodt-Moller PC. Transurethral interstitial laser coagulation of the prostate and transurethral microwave thermotherapy vs transurethral resection or incision of the prostate: results of a randomized, controlled study in patients with symptomatic benign prostatic hyperplasia. BJU Int 2002; 90:853-862.
45. Kuntzman RS, Malek RS, Barrett DM, Bostwick DG. High-power (60-watt) potassium-titanyl-phosphate laser vaporization prostatectomy in living canines and in human and canine cadavers. Urology 1997; 49:703-708.
46. Malek RS, Barrett DM, Kuntzman RS. High-power potassium-titanyl-phosphate (KTP/532) laser vaporization prostatectomy: 24 hours later. Urology 1998; 51:254-256.
47. Malek RS, Kuntzman RS, Barrett DM. High power potassium-titanyl-phosphate laser vaporization prostatectomy. J Urol 2000; 163:1730-1733.
48. Hai MA, Malek RS. Photoselective vaporization of the prostate: initial experience with a new 80 W KTP laser for the treatment of benign prostatic hyperplasia. J Endourol 2003; 17:93-96.